Save your place

Sign in to WhoBought

Please try again later.

Viking Therapeutics, Inc. (VKTX) institutional ownership

Latest close $34.87 Jul 27, 2026
Market cap$3.6B 52-week range SectorHealthcare
Funds holding · Q1 2026
396
reported VKTX position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Net bought $41M
216 buyers · 180 sellers

Viking Therapeutics, Inc. (VKTX) price and institutional activity

Dates

Q1 2026

$355M bought by 216 investors
Two Sigma Investments, LP$64MAmerican Century Companies Inc$57M +214 more
$315M sold by 180 investors
Two Sigma Advisers, LP-$68MJane Street Group, LLC-$24M +178 more
Bought Sold Totals per quarter; hover a bar for the names.

Viking Therapeutics, Inc. (VKTX) institutional activity · 396

Investor Type Est. change Change Δ Own Date
Two Sigma Advisers, LP · Exited −$68M
Change −2.1M Δ Own −100.0% Date Q1 2026
Two Sigma Advisers, LP Exited· Q1 2026 −$68M −2.1M −100.0% Q1 2026
Two Sigma Investments, LP · Added +$64M
Change +2.0M Δ Own +82.0% Date Q1 2026
Two Sigma Investments, LP Added· Q1 2026 +$64M +2.0M +82.0% Q1 2026
American Century Companies Inc · Added +$57M
Change +1.8M Date Q1 2026
American Century Companies Inc Added· Q1 2026 +$57M +1.8M Q1 2026
Raymond James Financial Inc · Added +$37M
Change +1.2M Date Q1 2026
Raymond James Financial Inc Added· Q1 2026 +$37M +1.2M Q1 2026
Vestal Point Capital, LP · New +$29M
Change +914K Date Q1 2026
Vestal Point Capital, LP New· Q1 2026 +$29M +914K Q1 2026
Jane Street Group, LLC · Reduced −$24M
Change −752K Date Q1 2026
Jane Street Group, LLC Reduced· Q1 2026 −$24M −752K Q1 2026
Susquehanna International Group, LLP · Reduced −$23M
Change −718K Date Q1 2026
Susquehanna International Group, LLP Reduced· Q1 2026 −$23M −718K Q1 2026
Exoduspoint Capital Management, LP · Reduced −$21M
Change −653K Date Q1 2026
Exoduspoint Capital Management, LP Reduced· Q1 2026 −$21M −653K Q1 2026
Artia Global Partners LP · Reduced −$17M
Change −539K Date Q1 2026
Artia Global Partners LP Reduced· Q1 2026 −$17M −539K Q1 2026
FMR LLC · Reduced −$17M
Change −533K Δ Own −8.1% Date Q1 2026
FMR LLC Reduced· Q1 2026 −$17M −533K −8.1% Q1 2026
Citadel Advisors LLC Reduced· Q1 2026 −$15M −470K −27.1% Q1 2026
BNP Paribas Financial Markets · Reduced −$15M
Change −452K Date Q1 2026
BNP Paribas Financial Markets Reduced· Q1 2026 −$15M −452K Q1 2026
Barclays PLC · Reduced −$14M
Change −446K Date Q1 2026
Barclays PLC Reduced· Q1 2026 −$14M −446K Q1 2026
UBS Group AG · Added +$13M
Change +413K Date Q1 2026
UBS Group AG Added· Q1 2026 +$13M +413K Q1 2026
Vanguard · Added +$12M
Change +372K Date Q1 2026
Vanguard Added· Q1 2026 +$12M +372K Q1 2026
Data through Q1 2026 · filed Jun 3, 2026
15 of 396

Famous investor activity in Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics, Inc. (VKTX) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Chen Hubert C. · Officer Grant (A) 190K
Owned 190K Trade date Jun 1, 2026 Filed date Jun 3, 2026
Chen Hubert C. Officer Grant (A) 190K 190K Jun 1, 2026 Jun 3, 2026
Aubuchon Neil William · Officer Buy +$150K
Price $33.50 Qty +4K Owned 4K Trade date Mar 10, 2026 Filed date Mar 10, 2026
Aubuchon Neil William Officer Buy $33.50 +4K +$150K 4K Mar 10, 2026 Mar 10, 2026
Aubuchon Neil William · Officer Grant (A) 180K
Owned 180K Trade date Jan 12, 2026 Filed date Jan 26, 2026
Aubuchon Neil William Officer Grant (A) 180K 180K Jan 12, 2026 Jan 26, 2026
Zante Greg · Officer 4 operations −$1.9M
Price $32.09–$34.24 Qty −58K Owned 190K Trade date Jan 5, 2026 Filed date Jan 5, 2026
Zante Greg Officer 4 operations $32.09–$34.24 −58K −$1.9M 190K Jan 5, 2026 Jan 5, 2026
Mancini Marianna · Officer 4 operations −$1.9M
Price $32.29–$35.07 Qty −58K Owned 409K Trade date Jan 5, 2026 Filed date Jan 5, 2026
Mancini Marianna Officer 4 operations $32.29–$35.07 −58K −$1.9M 409K Jan 5, 2026 Jan 5, 2026
Lian Brian · Director, Officer 4 operations −$7.7M
Price $32.29–$35.07 Qty −233K Owned 2.6M Trade date Jan 5, 2026 Filed date Jan 5, 2026
Lian Brian Director, Officer 4 operations $32.29–$35.07 −233K −$7.7M 2.6M Jan 5, 2026 Jan 5, 2026
Zante Greg · Officer 3 operations 164K
Owned 91K Trade date Jan 2, 2026 Filed date Jan 5, 2026
Zante Greg Officer 3 operations 164K 91K Jan 2, 2026 Jan 5, 2026
Mancini Marianna · Officer 3 operations 164K
Owned 91K Trade date Jan 2, 2026 Filed date Jan 5, 2026
Mancini Marianna Officer 3 operations 164K 91K Jan 2, 2026 Jan 5, 2026
Lian Brian · Director, Officer 3 operations 479K
Owned 176K Trade date Jan 2, 2026 Filed date Jan 5, 2026
Lian Brian Director, Officer 3 operations 479K 176K Jan 2, 2026 Jan 5, 2026
Singleton J. Matthew · Director 2 operations 24K
Owned 20K Trade date Jan 2, 2026 Filed date Jan 5, 2026
Singleton J. Matthew Director 2 operations 24K 20K Jan 2, 2026 Jan 5, 2026
Macartney Lawson · Director 2 operations 24K
Owned 20K Trade date Jan 2, 2026 Filed date Jan 5, 2026
Macartney Lawson Director 2 operations 24K 20K Jan 2, 2026 Jan 5, 2026
Rowland Charles A. Jr · Director 2 operations 24K
Owned 20K Trade date Jan 2, 2026 Filed date Jan 5, 2026
Rowland Charles A. Jr Director 2 operations 24K 20K Jan 2, 2026 Jan 5, 2026
Foehr Matthew W. · Director Sell −$562K
Price $35.11 Qty −16K Owned 132K Trade date Jan 2, 2026 Filed date Jan 5, 2026
Foehr Matthew W. Director Sell $35.11 −16K −$562K 132K Jan 2, 2026 Jan 5, 2026
Foehr Matthew W. · Director 2 operations 0
Price $3.33 Owned 0 Trade date Jan 2, 2026 Filed date Jan 5, 2026
Foehr Matthew W. Director 2 operations $3.33 0 0 Jan 2, 2026 Jan 5, 2026
Foehr Matthew W. · Director 2 operations 24K
Owned 20K Trade date Jan 2, 2026 Filed date Jan 5, 2026
Foehr Matthew W. Director 2 operations 24K 20K Jan 2, 2026 Jan 5, 2026
15 of 25
15 of 25 Sign in to continue to older insider transactions.

Viking Therapeutics, Inc. (VKTX) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Vanguard Capital Management 5.9M
% of shares outstanding 5.1% Filing date Apr 30, 2026
Vanguard Capital Management 5.9M 5.1% Apr 30, 2026
1 of 1

Viking Therapeutics, Inc. (VKTX) ownership FAQ

Who owns VKTX?

396 reporting institutions disclosed VKTX position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.